In the third quarter of 2019, J&J reported revenue of $20.73 billion, beating the $20.07 billion analysts expected. In addition, the company’s adjusted earnings per share hit $2.12 versus an expected $2.01.
J&J also raised its full-year guidance, expecting earnings between $8.62 to $8.67 per share and revenue in the range of $81.8 billion to $82.3 billion.
The strong third quarter as attributed to higher sales of cancer and other prescription drugs, according to CNBC.
In particular, the company’s pharmaceutical business posted revenue of $10.88 billion, higher than the $10.41 billion expected. Its medical device unit reported $6.3 billion, better than the $6.27 expected.
J&J is currently facing thousands of lawsuits, ranging from claims that its talc-based baby powder causes cancer to allegations that it fueled the opioid crisis.
The company was ordered by an Oklahoma judge in August to pay $572 million for its part in the opioid crisis in that state and was ordered Oct. 9 by a Philadelphia jury to pay $8 billion in punitive damages for downplaying the risk its antipsychotic drug Risperdal could cause breast growth in boys.
J&J did not report its litigation expenses for the third quarter.
Read the full article here.
More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020
More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020
